Literature DB >> 33170240

Effect of e-Cigarettes Plus Counseling vs Counseling Alone on Smoking Cessation: A Randomized Clinical Trial.

Mark J Eisenberg1,2,3, Andréa Hébert-Losier1, Sarah B Windle1, Todd Greenspoon4, Tim Brandys5, Tamàs Fülöp6, Thang Nguyen7, Stéphane Elkouri8, Martine Montigny9, Igor Wilderman10, Olivier F Bertrand11, Joanna Alexis Bostwick12, John Abrahamson13, Yves Lacasse11, Smita Pakhale14, Josselin Cabaussel1, Kristian B Filion1,2.   

Abstract

Importance: Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial. Objective: To evaluate e-cigarettes with individual counseling for smoking cessation. Design, Setting, and Participants: A randomized clinical trial enrolled adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites (801 individuals screened; 274 ineligible and 151 declined). Manufacturing delays resulted in early termination (376/486 participants, 77% of target). Outcomes through 24 weeks (March 2020) are reported. Interventions: Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks. All groups received individual counseling. Main Outcomes and Measures: The primary end point was point prevalence abstinence (7-day recall, biochemically validated using expired carbon monoxide) at 12 weeks, changed from 52 weeks following early termination. Participants missing data were assumed to be smoking. The 7 secondary end points, examined at multiple follow-ups, were point prevalence abstinence at other follow-ups, continuous abstinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to adverse effects, and treatment adherence.
Results: Among 376 randomized participants (mean age, 52 years; 178 women [47%]), 299 (80%) and 278 (74%) self-reported smoking status at 12 and 24 weeks, respectively. Point prevalence abstinence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 weeks (21.9% vs 9.1%; risk difference [RD], 12.8 [95% CI, 4.0 to 21.6]) but not 24 weeks (17.2% vs 9.9%; RD, 7.3 [95% CI, -1.2 to 15.7]). Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly different from counseling alone at 12 weeks (17.3% vs 9.1%; RD, 8.2 [95% CI, -0.1 to 16.6]), but was significantly greater at 24 weeks (20.5% vs 9.9%; RD, 10.6 [95% CI, 1.8 to 19.4]). Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only: 88 [73%]), with the most common being cough (64%) and dry mouth (53%). Conclusions and Relevance: Among adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone significantly increased point prevalence abstinence at 12 weeks. However, the difference was no longer significant at 24 weeks, and trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed. Trial Registration: ClinicalTrials.gov Identifier: NCT02417467.

Entities:  

Mesh:

Year:  2020        PMID: 33170240      PMCID: PMC7656286          DOI: 10.1001/jama.2020.18889

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Developmental history of the Glover-Nilsson smoking behavioral questionnaire.

Authors:  Elbert D Glover; Fredrik Nilsson; Ake Westin; Penny N Glover; Molly T Laflin; Birger Persson
Journal:  Am J Health Behav       Date:  2005 Sep-Oct

2.  A Pragmatic Trial of E-Cigarettes, Incentives, and Drugs for Smoking Cessation.

Authors:  Scott D Halpern; Michael O Harhay; Kathryn Saulsgiver; Christine Brophy; Andrea B Troxel; Kevin G Volpp
Journal:  N Engl J Med       Date:  2018-05-23       Impact factor: 91.245

3.  A Naturalistic, Randomized Pilot Trial of E-Cigarettes: Uptake, Exposure, and Behavioral Effects.

Authors:  Matthew J Carpenter; Bryan W Heckman; Amy E Wahlquist; Theodore L Wagener; Maciej L Goniewicz; Kevin M Gray; Brett Froeliger; K Michael Cummings
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-10       Impact factor: 4.254

4.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

5.  E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion.

Authors:  Boris Reidel; Giorgia Radicioni; Phillip W Clapp; Amina A Ford; Sabri Abdelwahab; Meghan E Rebuli; Prashamsha Haridass; Neil E Alexis; Ilona Jaspers; Mehmet Kesimer
Journal:  Am J Respir Crit Care Med       Date:  2018-02-15       Impact factor: 21.405

6.  Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.

Authors:  Benjamin C Blount; Mateusz P Karwowski; Peter G Shields; Maria Morel-Espinosa; Liza Valentin-Blasini; Michael Gardner; Martha Braselton; Christina R Brosius; Kevin T Caron; David Chambers; Joseph Corstvet; Elizabeth Cowan; Víctor R De Jesús; Paul Espinosa; Carolina Fernandez; Cory Holder; Zsuzsanna Kuklenyik; Jennifer D Kusovschi; Cody Newman; Gregory B Reis; Jon Rees; Chris Reese; Lalith Silva; Tiffany Seyler; Min-Ae Song; Connie Sosnoff; Carleen R Spitzer; Denise Tevis; Lanqing Wang; Cliff Watson; Mark D Wewers; Baoyun Xia; Douglas T Heitkemper; Isaac Ghinai; Jennifer Layden; Peter Briss; Brian A King; Lisa J Delaney; Christopher M Jones; Grant T Baldwin; Anita Patel; Dana Meaney-Delman; Dale Rose; Vikram Krishnasamy; John R Barr; Jerry Thomas; James L Pirkle
Journal:  N Engl J Med       Date:  2019-12-20       Impact factor: 91.245

7.  EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.

Authors:  Pasquale Caponnetto; Davide Campagna; Fabio Cibella; Jaymin B Morjaria; Massimo Caruso; Cristina Russo; Riccardo Polosa
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Association between duration of use of pharmacotherapy and smoking cessation: findings from a national survey.

Authors:  Mohammad Siahpush; Raees A Shaikh; Molly McCarthy; Asia Sikora Kessler; Melissa Tibbits; Gopal K Singh
Journal:  BMJ Open       Date:  2015-01-13       Impact factor: 2.692

9.  A Randomized Controlled Trial Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation in the General Population: E3 Trial Design.

Authors:  Andréa Hébert-Losier; Kristian B Filion; Sarah B Windle; Mark J Eisenberg
Journal:  CJC Open       Date:  2020-03-19

10.  Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020.

Authors:  Sascha Ellington; Phillip P Salvatore; Jean Ko; Melissa Danielson; Lindsay Kim; Alissa Cyrus; Megan Wallace; Amy Board; Vikram Krishnasamy; Brian A King; Dale Rose; Christopher M Jones; Lori A Pollack
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-01-17       Impact factor: 17.586

View more
  16 in total

1.  Effectiveness of Non-Nicotinic E-Cigarettes to Reduce Cue- and Abstinence-Induced Cigarette Craving in Non-Treatment Seeking Daily Dependent Smokers.

Authors:  Ginnie Ng; Sophia Attwells; Peter Selby; Laurie Zawertailo
Journal:  Psychopharmacology (Berl)       Date:  2021-01-30       Impact factor: 4.530

2.  Investigating the effect of e-cigarette use on quitting smoking in adults aged 25 years or more using the PATH study.

Authors:  Peter N Lee; John S Fry
Journal:  F1000Res       Date:  2020-09-07

3.  Factors associated with past-year attempts to quit e-cigarettes among current users: Findings from the Population Assessment of Tobacco and Health Wave 4 (2017-2018).

Authors:  Rachel L Rosen; Marc L Steinberg
Journal:  Drug Alcohol Depend       Date:  2021-08-28       Impact factor: 4.852

4.  Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame.

Authors:  Neal L Benowitz; Gideon St Helen; Evangelia Liakoni
Journal:  J Clin Pharmacol       Date:  2021-08       Impact factor: 2.860

Review 5.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Ailsa R Butler; Nicola Lindson; Chris Bullen; Rachna Begh; Annika Theodoulou; Caitlin Notley; Nancy A Rigotti; Tari Turner; Thomas R Fanshawe; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2021-09-14

6.  Electronic Nicotine Delivery Systems (ENDS) Use and Pregnancy I: ENDS Use Behavior During Pregnancy.

Authors:  Elise E DeVito; Tessa Fagle; Alicia M Allen; Raina D Pang; Nicole Petersen; Philip H Smith; Andrea H Weinberger
Journal:  Curr Addict Rep       Date:  2021-07-13

Review 7.  Multiple Tobacco Product Use Conceptual Framework: A 2021 Update on Evidence.

Authors:  Dana Rubenstein; Lauren R Pacek; F Joseph McClernon
Journal:  Nicotine Tob Res       Date:  2022-07-13       Impact factor: 5.825

8.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Nicola Lindson; Chris Bullen; Rachna Begh; Annika Theodoulou; Caitlin Notley; Nancy A Rigotti; Tari Turner; Ailsa R Butler; Thomas R Fanshawe; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2021-04-29

Review 9.  E-Cigarettes and Cardiopulmonary Health: Review for Clinicians.

Authors:  Loren E Wold; Robert Tarran; Evan W Neczypor; Matthew J Mears; Arunava Ghosh; M Flori Sassano; Richard J Gumina
Journal:  Circulation       Date:  2022-01-18       Impact factor: 29.690

10.  Respiratory Symptom Incidence among People Using Electronic Cigarettes, Combustible Tobacco, or Both.

Authors:  Krishna P Reddy; Eli Schwamm; Sara Kalkhoran; Farzad Noubary; Rochelle P Walensky; Nancy A Rigotti
Journal:  Am J Respir Crit Care Med       Date:  2021-07-15       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.